The chimeric antigen receptor t cell therapy has now entered clinical trials for cancer

The Chimeric Antigen Receptor T Cell Therapy Has Now Entered Clinical Trials for Cancer Tags: CAR, NKG2D, TIM, therapy Previously, the chimeric antigen receptor design had entered the clinical test research. CAR therapy has a wide range of applications in many different cancer treatments, and later studies have shown that CAR expression can not only eliminate tumors in the body of experimental animals, but also effectively inhibit the recurrence of cancer.

CN-CS1 is the first therapy for the first time in the clinical trial, which is a kind of autologous CAR T cell therapy to recruit NKG2D cell receptor. NKG2D, as a kind of natural killer cell receptor, can target most ligands in tumors, including blood cancer and solid tumor. Previous clinical trials had been carried out in blood cancers, such as leukemia and myeloma, and the value of the clinical trials has been widely used in the field of cancer research, which has more far-reaching prospects.

As with the new generation technologies, many other therapies are currently undergoing clinical development. A new generation technology platform can combine CAR T cells with another kind of innovative TCR- inhibitor molecules (TIMs). TIMs can be used to study T cells with CAR therapy in healthy donors, so as to avoid the Graft Versus Host Disease (GVHD). Once successful, TIM/CAR therapy will be used to reduce the duration of the treatment, and significantly reduce patient expenditure.

The new therapy on the clinical course of treatment is something to be celebrates. It has very important significance for the development of the new type of cancer immune therapy. CAR cell therapy potential will also bring great hope to improve a patient's health.

Source: http://www.imfaceplate.com/cart/the-chimeric-antigen-receptor-t-cell-therapy-has-nowentered-clinical-trials-for-cancer